子宫内膜异位症术后应用曲普瑞林和米非司酮治疗的疗效观察

The efficacy of triptorelin or mifepristone for endometriosis after surgery

目的探讨术后应用曲普瑞林和米非司酮治疗子宫内膜异位症患者的临床价值。方法将我院从2007年8月至2011年10月收治的120例子宫内膜异位症患者，术后随机分为A组40例、B组40例，分别应用曲普瑞林和米非司酮治疗，C组40例按常规治疗，疗程6个月，进行术后的疗效观察。结果A、B两组患者术后应用曲普瑞林和米非司酮，痛经和月经量得到不同程度缓解，A、B组治疗有效率（A组97．5％，B组95％）高于C组（75％）。A组的阴道异常出血率（5％）明显低于B组（22．5％）和c组（45％），B组低于C组，差异有统计学意义（P〈0．05）。结论手术作为EMs的主要治疗手段，术后应用米非司酮、曲普瑞林等药物可明显改善症状。曲普瑞林因疗效显著，不良反应小等优点，可作为EMs术后巩固治疗的首选药物。

Objective To explore the clinical efficacy of triptorelin or mifepristone for endometriosis after surgery. Methods 120 patients with endometriosis who had been hospitalized during the period of August 2007 to October 2011 were randomly assigned to receive triptorelin （ 40 patients, group A ）, mifepristone （ 40 patients, group B ）, or conventional therapy （ 40 patients, group C ） for six months after surgery. The efficacy was observed. Results Dysmeuorrhea and menorrhagia were relieved at different degrees in groups A and B. The effectiveness rate was 97.5% in group A and 95% in group B, which was higher than that in group C （ 75% ）. The rate of abnormal vaginal hemorrhage was significantly lower in group A （ 5% ） than in group B （ 22.5% ） and group C （ 45% ）, with a significant difference （ P〈 0.05 ）. Conclusions Surgery is the major therapy for endometriosis. Postoperative uses of triptorelin or mifepristone can evidently improve symptoms of the disorder. Triptorelin can be used as th medication of first choice for consolidation treatment due to better efficacy and fewer adverse reactions.